Trial
NCT02556593
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sun Yat-sen University
Collaborators
—
Condition
Non-Small Cell Lung Carcinoma
Intervention
IMRT
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-12